Pilot Study on Evaluating the Geroprotective Effect of Metformin

Subjects in both the metformin hydrochloride extended-release tablets treatment group and the placebo group received two tablets (500 mg each) once daily after dinner, continuing for a one-year period of drug intervention.

Inclusion criteria

：

• Male
• Age 55-65; 18-28;
• Able to understand and execute instructions;
• After reading the consent form, be able to answer questions about the study and demonstrate understanding of the protocol;
• Be able to participate in regular follow-up visits.

Exclusion criteria

• Severe chronic or acute disease: cancer, clinically significant congestive heart failure, chronic obstructive pulmonary disease (COPD), previous or new-onset diabetes, inflammatory state, serum creatinine >1.5 mg/dl , active liver disease, History of metabolic acidosis, poorly controlled hypertension, epilepsy, recent (within 3 months) cardiovascular events (MI, PTCA, CABG, stroke), severe renal insufficiency, inflammatory bowel disease, persistent glucocorticoids Treatment; neurological diseases such as dementia, AD, PD, etc.; infectious diseases such as HIV, hepatitis, tuberculosis, etc.; severe autoimmune diseases;
• BMI<18.5 or BMI>30;
• Persistent alcohol or drug abuse;
• Treatment with drugs known to affect glucose metabolism (other diabetes drugs, systemic glucocorticoids, niacin);
• Hypersensitivity to metformin or any component of the preparation;
• Have taken metformin, low-dose aspirin, acarbose, vitamin C in the recent (3 months);
• Unable to provide informed consent;
• Other circumstances in which the researcher believes that the physical factors of the participants may adversely affect the research process or results.